Anti-41-BB (CD137) agonistic antibody. Anti-41-BB (CD137) agonistic antibody has just entered clinical testing. Although no clinical data are available yet, there are strong preclinical justifications for its use in patients with melanoma.[34] This antibody is capable of augmenting antigen-specific T-cell responses, and its use with a peptide vaccine resulted in regression of established poorly immunogenic tumors in mice.[35] Of note, the combination of anti-CD137 and CTLA-4 appeared to decrease autoimmune side effects yet increase antitumor effects compared with either antibody alone.The recent explosion of knowledge on immune regulatory pathways and receptor-ligand pairs on T cells has facilitated several innovative phase 1/2 trials and the development of 2 antibodies in no less than 5 registration trials. Patients with metastatic melanoma have never before had access to as wide a variety of promising agents.
As you can see, they are making great in roads in finding a cure or just stabilizing the progression of the disease.
Jimmy B.
No comments:
Post a Comment